Global NGS Based Molecular Diagnostic Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2033

NGS Based Molecular Diagnostic Market Size

• The global NGS based molecular diagnostic market size was valued at USD 2.34 billion in 2025 and is expected to reach USD 3.82 billion by 2033, at a CAGR of 6.35% during the forecast period
• The market growth is largely fueled by the increasing adoption of next-generation sequencing (NGS) technologies and continuous technological advancements in genomic analysis, leading to enhanced digitalization and data-driven decision-making across clinical diagnostics and research settings
• Furthermore, rising demand for highly accurate, rapid, and comprehensive molecular diagnostic solutions is establishing NGS-based testing as a preferred approach for disease detection, precision medicine, and personalized treatment planning. These converging factors are accelerating the uptake of NGS-based molecular diagnostic solutions, thereby significantly boosting the market’s growth

NGS Based Molecular Diagnostic Market Analysis

• NGS-based molecular diagnostics, which enable high-throughput and highly precise genomic analysis, are becoming increasingly vital in modern clinical diagnostics and research settings due to their ability to support early disease detection, precision medicine, and personalized treatment strategies across oncology, infectious diseases, and genetic disorders
• The growing demand for NGS-based diagnostics is primarily driven by the rising prevalence of cancer and genetic diseases, increasing adoption of precision medicine, declining sequencing costs, and continuous technological advancements in sequencing platforms, bioinformatics, and data analytics
• North America dominated the NGS-based molecular diagnostic market in 2025, accounting for approximately 42% of global revenue, supported by strong research infrastructure, high healthcare spending, early adoption of advanced genomic technologies, and the presence of major industry players, with the U.S. leading in clinical NGS testing and companion diagnostics adoption
• Asia-Pacific is expected to be the fastest-growing region in the NGS-based molecular diagnostic market during the forecast period, driven by expanding healthcare infrastructure, increasing government funding for genomics research, rising awareness of personalized medicine, and growing diagnostic demand in countries such as China, India, and Japan
• The oncology segment dominated the largest market revenue share of 38.6% in 2025, driven by the rising global burden of cancer and the growing adoption of precision medicine

Report Scope and NGS Based Molecular Diagnostic Market Segmentation           

NGS Based Molecular Diagnostic Market Trends

“Advancements in Sequencing Technologies and Clinical Application Expansion”

• A significant and accelerating trend in the global NGS based molecular diagnostic market is the continuous advancement of next-generation sequencing technologies, enabling faster sequencing, higher accuracy, and reduced turnaround times for clinical diagnostics
• For instance, in June 2024, Illumina launched an updated version of its NovaSeq X Series, offering higher throughput and improved data quality, supporting large-scale genomic testing in oncology and rare disease diagnostics
• The adoption of NGS-based diagnostics is expanding beyond research settings into routine clinical practice, particularly for applications such as oncology companion diagnostics, hereditary disease screening, and infectious disease detection
• Improved sample preparation workflows, automation of library preparation, and enhanced bioinformatics pipelines are streamlining laboratory operations and reducing operational complexity for diagnostic laboratories
• This trend toward more efficient, scalable, and clinically validated sequencing solutions is reshaping diagnostic decision-making by enabling comprehensive genomic profiling and personalized treatment strategies
• The growing availability of regulatory-approved NGS-based diagnostic assays is further supporting market adoption across hospitals, reference laboratories, and specialized diagnostic centers

NGS Based Molecular Diagnostic Market Dynamics

Driver

“Rising Prevalence of Genetic Disorders and Increasing Demand for Precision Medicine”

• The rising incidence of cancer, inherited genetic disorders, and infectious diseases is a major driver for the growing adoption of NGS-based molecular diagnostic solutions
• For instance, in April 2025, Thermo Fisher Scientific expanded its Oncomine Precision Assay portfolio, addressing the increasing demand for comprehensive tumor profiling and targeted therapy selection in oncology care
• The growing emphasis on precision medicine and personalized treatment approaches is encouraging healthcare providers to adopt NGS-based diagnostics for accurate mutation detection and risk assessment
• Increasing investments in genomic research, supported by government initiatives and private funding, are accelerating the integration of NGS technologies into clinical diagnostics
• In addition, rising awareness among clinicians regarding the clinical value of early and accurate molecular diagnosis is contributing to the increased utilization of NGS-based diagnostic tests across multiple therapeutic areas

Restraint/Challenge

“High Testing Costs and Data Interpretation Complexity”

• The relatively high cost associated with NGS-based diagnostic testing, including sequencing instruments, reagents, and data analysis infrastructure, poses a challenge to widespread adoption, particularly in low- and middle-income regions
• For instance, in September 2023, several mid-sized diagnostic laboratories in Asia-Pacific reported delays in adopting NGS platforms due to the high initial investment and ongoing operational expenses
• The complexity of data analysis and interpretation requires skilled bioinformatics professionals, which can limit adoption in healthcare settings with limited technical expertise
• Regulatory requirements for clinical validation, data privacy, and quality assurance add further challenges for market participants and diagnostic laboratories
• Overcoming these challenges through cost reduction strategies, simplified bioinformatics solutions, workforce training, and supportive reimbursement policies will be critical for sustained growth of the NGS based molecular diagnostic market

NGS Based Molecular Diagnostic Market Scope

The market is segmented on the basis of application and end users.

• By Application

On the basis of application, the NGS Based Molecular Diagnostic market is segmented into microbiology, infectious diseases, oncology, genetic tests, and other applications. The oncology segment dominated the largest market revenue share of 38.6% in 2025, driven by the rising global burden of cancer and the growing adoption of precision medicine. NGS-based diagnostics play a critical role in identifying tumor-specific genetic mutations, enabling targeted therapy selection and personalized treatment planning. Oncology applications extensively use NGS for solid tumors, hematological malignancies, and companion diagnostics. Increasing demand for early cancer detection and monitoring of treatment response supports dominance. Pharmaceutical and biotechnology companies heavily rely on NGS oncology diagnostics during drug development and clinical trials. The growing number of FDA-approved companion diagnostics further strengthens adoption. Advancements in sequencing accuracy and reduced turnaround time enhance clinical utility. Hospitals increasingly integrate NGS into routine oncology workflows. Reimbursement support in developed markets accelerates usage. Academic research and clinical oncology collaborations promote innovation. The expanding use of liquid biopsy techniques further boosts demand. Overall, oncology remains the most established and revenue-generating application segment globally.

The infectious diseases segment is anticipated to witness the fastest CAGR of 18.9% from 2026 to 2033, driven by the growing need for rapid, accurate pathogen detection and outbreak surveillance. NGS-based diagnostics enable comprehensive identification of bacteria, viruses, fungi, and antimicrobial resistance genes in a single test. Rising prevalence of emerging and re-emerging infectious diseases supports rapid adoption. Public health agencies increasingly use NGS for epidemiological tracking and variant monitoring. The COVID-19 pandemic significantly accelerated awareness and investment in genomic diagnostics. Hospitals prefer NGS for complex infections where conventional methods fail. Advances in sequencing speed and cost reduction improve accessibility. NGS supports real-time monitoring of viral mutations and drug resistance. Integration with bioinformatics platforms enhances clinical interpretation. Increasing government funding for infectious disease preparedness drives growth. Adoption in microbiology laboratories continues to expand. The growing emphasis on precision diagnostics in infectious disease management ensures sustained high CAGR.

• By End Users

On the basis of end users, the NGS Based Molecular Diagnostic market is segmented into research centres and academics, hospitals and clinical laboratories, and others. The hospitals and clinical laboratories segment accounted for the largest market revenue share of 46.8% in 2025, driven by the increasing integration of NGS into routine clinical diagnostics. Hospitals utilize NGS for oncology profiling, infectious disease detection, and rare disease diagnosis. Clinical laboratories benefit from high-throughput sequencing capabilities and automation, enabling faster turnaround times. Growing demand for personalized medicine encourages hospitals to adopt NGS platforms. Expansion of molecular pathology departments supports dominance. Hospitals leverage NGS for companion diagnostics and treatment monitoring. Strong collaboration between hospitals and pharmaceutical companies enhances adoption. Regulatory approvals for clinical NGS tests strengthen confidence. Availability of skilled professionals supports implementation. Reimbursement coverage in developed regions boosts hospital usage. Centralized laboratory models increase test volumes. Continuous investment in diagnostic infrastructure sustains dominance. Hospitals remain the primary commercial users of NGS-based molecular diagnostics worldwide.

The research centres and academics segment is expected to witness the fastest CAGR of 17.4% from 2026 to 2033, driven by rising genomic research activities and government-funded research initiatives. Academic institutions increasingly use NGS for large-scale population genomics, disease association studies, and biomarker discovery. Growing collaboration between academia and biotechnology companies accelerates adoption. Research centers rely on NGS for drug discovery and translational research. Increasing funding from public and private organizations supports infrastructure expansion. NGS enables high-resolution genetic analysis essential for advanced research applications. Declining sequencing costs improve accessibility for academic institutions. Growth in precision medicine research fuels demand. Research laboratories benefit from flexible and scalable NGS platforms. Expansion of genomics education programs supports long-term adoption. Academic participation in global genome projects boosts usage. Innovation in bioinformatics tools enhances research output. Overall, research centres represent the fastest-growing end-user segment in the NGS molecular diagnostics market.

NGS Based Molecular Diagnostic Market Regional Analysis

• North America dominated the NGS-based molecular diagnostic market in 2025, accounting for approximately 42% of global revenue
• The region’s leadership is supported by strong research infrastructure, high healthcare expenditure, early adoption of advanced genomic technologies, and the widespread integration of next-generation sequencing in clinical diagnostics
• The presence of major industry players, advanced laboratory networks, and favorable reimbursement frameworks has further strengthened market growth across oncology, rare disease diagnostics, and infectious disease testing

U.S. NGS-Based Molecular Diagnostic Market Insight

The U.S. NGS-based molecular diagnostic market captured the largest revenue share within North America in 2025, driven by extensive use of NGS in clinical testing, companion diagnostics, and precision medicine applications. Strong adoption across hospitals, reference laboratories, and academic research institutions, along with significant federal and private investments in genomics research, continues to propel market expansion. The country remains a global leader in clinical NGS testing and biomarker-driven therapy selection.

Europe NGS-Based Molecular Diagnostic Market Insight

The Europe NGS-based molecular diagnostic market is projected to grow steadily during the forecast period, supported by increasing adoption of genomic diagnostics in oncology and inherited disease screening. Government-supported research initiatives, growing collaboration between academic institutions and biotechnology companies, and expanding use of NGS in clinical laboratories are contributing to market growth across the region.

U.K. NGS-Based Molecular Diagnostic Market Insight

The U.K. market is anticipated to grow at a noteworthy CAGR, driven by strong government backing for genomic medicine programs and the integration of NGS into national healthcare services. Initiatives such as large-scale population genomics projects and increased use of NGS in cancer diagnostics and rare disease identification are supporting sustained market growth.

Germany NGS-Based Molecular Diagnostic Market Insight

Germany NGS-based molecular diagnostic market is expected to witness considerable growth in the NGS-Based Molecular Diagnostic market, supported by its advanced healthcare infrastructure, strong biotechnology sector, and rising demand for precision diagnostics. The increasing use of NGS in clinical research, oncology testing, and personalized treatment planning is driving adoption across hospitals and specialized diagnostic laboratories.

Asia-Pacific NGS-Based Molecular Diagnostic Market Insight

Asia-Pacific NGS-based molecular diagnostic market is expected to be the fastest-growing region in the NGS-Based Molecular Diagnostic market during the forecast period. Growth is driven by expanding healthcare infrastructure, increasing government funding for genomics research, rising awareness of personalized medicine, and growing diagnostic demand across China, India, Japan, and Southeast Asia. Improving access to sequencing technologies and declining sequencing costs are further accelerating market penetration.

China NGS-Based Molecular Diagnostic Market Insight

China NGS-based molecular diagnostic market accounted for the largest revenue share in the Asia-Pacific market in 2025, supported by strong government investment in genomics, rapid expansion of diagnostic laboratories, and growing adoption of NGS in oncology and infectious disease testing. Domestic sequencing platform development and increasing clinical validation of NGS-based diagnostics are key contributors to market growth.

Japan NGS-Based Molecular Diagnostic Market Insight

Japan’s NGS-based molecular diagnostic market is gaining momentum due to rising adoption of precision medicine, strong academic research capabilities, and increasing use of genomic testing in cancer care. Government support for genomic research and integration of NGS into clinical decision-making are further driving market expansion.

NGS Based Molecular Diagnostic Market Share

The NGS Based Molecular Diagnostic industry is primarily led by well-established companies, including:

• Illumina, Inc. (U.S.)
• Thermo Fisher Scientific, Inc. (U.S.)
• Qiagen N.V. (Netherlands)
• F. Hoffmann-La Roche Ltd (Switzerland)
• BGI Genomics (China)
• Agilent Technologies, Inc. (U.S.)
• PerkinElmer, Inc. (U.S.)
• NEB (New England Biolabs) (U.S.)
• Oxford Nanopore Technologies (U.K.)
• Exact Sciences Corporation (U.S.)
• Charles River Laboratories (U.S.)
• Genomic Health, Inc. (U.S.)
• Singlera Genomics (China)
• Macrogen, Inc. (South Korea)
• Guardant Health, Inc. (U.S.)
• Sophia Genetics (Switzerland)
• Adaptive Biotechnologies (U.S.)
• Fulgent Genetics (U.S.)
• Eurofins Scientific (Luxembourg)
• DNASTAR, Inc. (U.S.)

Latest Developments in Global NGS Based Molecular Diagnostic Market

• In September 2022, Illumina, Inc. unveiled its NovaSeq X Series, a new generation of high‑throughput sequencers designed to accelerate genomic medicine by enabling rapid sequencing of whole genomes at scale. This platform offered significantly higher throughput and sustainability features compared to previous models, supporting broad applications including clinical diagnostics, cancer genomics, and population health research
• In February 2023, Illumina delivered the first NovaSeq X Plus sequencer to the Broad Institute, marking the commercial rollout of one of the most advanced NGS platforms available. The delivery enabled researchers to undertake large‑scale genomic sequencing projects with improved accuracy and speed, supporting precision medicine and diagnostic research
• In January 2023, QIAGEN NV completed the acquisition of Verogen, Inc., strengthening its NGS technology portfolio. This acquisition expanded QIAGEN’s capabilities in next‑generation sequencing, particularly in human identification and forensic genomics, which complements its molecular diagnostics offerings and broadens clinical genomics reach
• In April 2023, Q² Solutions integrated Illumina’s NovaSeq X Plus platform into its laboratory infrastructure to enhance scalable NGS workflows and data quality for complex genomic studies. This adoption underscored a trend of major clinical and contract research organizations investing in cutting‑edge NGS technology to support precision medicine and diagnostics
• In August 2024, Illumina expanded its oncology assay offerings for the NovaSeq X Series, launching an advanced oncology menu including high‑throughput versions of TruSight Oncology 500 (TSO 500 HT) and TSO 500 ctDNA v2 for comprehensive genomic profiling. These assays enable more efficient and cost‑effective oncology testing using NGS platforms
• In June 2025, bioMérieux SA announced the acquisition of Day Zero Diagnostics, a U.S. company specializing in infectious disease diagnostics using genome sequencing and machine learning. This strategic move strengthened bioMérieux’s expertise in NGS‑based rapid diagnostics and antimicrobial resistance detection solutions, reflecting growing integration of sequencing and AI in clinical diagnostics
• In January 2025, Roche Diagnostics introduced the AVENIO Edge System, a fully automated sample‑to‑insight NGS platform designed for molecular pathology laboratories. This launch highlighted continued innovation in automated and streamlined NGS workflows tailored to clinical diagnostic environments
• In March 2025, Thermo Fisher Scientific expanded its Ion Torrent Genexus System with new oncology panels for lung and colorectal cancers, supporting in‑clinic genomic profiling and demonstrating the trend toward integrated NGS diagnostic panels for precision oncology care
• In May 2025, BGI Genomics partnered with India’s Apollo Hospitals to deploy population‑scale genetic screening programs using NGS technologies across urban and rural regions, underscoring the expanding role of NGS in public health screening and personalized diagnostics globally

SKU-61487